RapidAI receives FDA clearance for subdural hematoma alert module

RapidAI, a developer of artificial intelligence (AI) for critical medical conditions, announced it has received FDA clearance for its Rapid SDH, an AI module for automatically detecting hemispheric subdural hematomas. 

The tech notifies trauma teams across the health system automatically when a patient is suspected of having a hemispheric subdural hematoma or major brain hemorrhage, facilitating rapid intervention of what could be a serious critical emergency. 

RapidAI says the alerts are sent out in under a minute after the AI analyzes scans. 

"The FDA's clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and advancements in potential treatment options,” Amit Phadnis, CTO of RapidAI said in a statement. “Our goal is to continue to expand the capabilities and applications of our deep AI to deliver comprehensive clinical solutions that provide care teams with the crucial insights necessary to evaluate patients, streamline decision making, and expedite care for this common and dangerous disease.”